메뉴 건너뛰기




Volumn 135, Issue 6, 2011, Pages 979-980

Fixation time and HER2/neu assessment

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; HORMONE RECEPTOR; NEU DIFFERENTIATION FACTOR; NEUTRAL BUFFERED FORMALIN; UNCLASSIFIED DRUG;

EID: 79957694176     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPVRQS9UQTCZE5     Document Type: Letter
Times cited : (2)

References (8)
  • 1
    • 77957377568 scopus 로고    scopus 로고
    • Fixation time does not affect expression of HER2/neu: A pilot study
    • Ibarra JA, Rogers LW. Fixation time does not affect expression of HER2/neu: a pilot study. Am J Clin Pathol. 2010;134:594-596.
    • (2010) Am J Clin Pathol , vol.134 , pp. 594-596
    • Ibarra, J.A.1    Rogers, L.W.2
  • 2
    • 70350680445 scopus 로고    scopus 로고
    • Delay to formalin fixation effect on breast biomarkers
    • Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22:1457-1467.
    • (2009) Mod Pathol , vol.22 , pp. 1457-1467
    • Khoury, T.1    Sait, S.2    Hwang, H.3
  • 5
    • 34548210998 scopus 로고    scopus 로고
    • Begin at the beginning, with the tissue! The key message underlying the ASCO/CAP task-force guideline recommendations for HER2 testing
    • DOI 10.1097/PAI.0b013e3181250254, PII 0012903920070900000001
    • Yaziji H, Taylor CR. Begin at the beginning, with the tissue! the key message underlying the ASCO/CAP Task-force Guideline Recommendations for HER2 testing [editorial]. Appl Immunohistochem Mol Morphol. 2007;15:239-241. (Pubitemid 47329912)
    • (2007) Applied Immunohistochemistry and Molecular Morphology , vol.15 , Issue.3 , pp. 239-241
    • Yaziji, H.1    Taylor, C.R.2
  • 6
    • 61349131323 scopus 로고    scopus 로고
    • Prediction of HER2 gene status in HER2 2+ invasive breast cancer: A study of 108 cases comparing ASCO/CAP and FDA recommendations
    • Chibon F, de Mascarel I, Sierankowski G, et al. Prediction of HER2 gene status in HER2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol. 2009;22:403-409.
    • (2009) Mod Pathol , vol.22 , pp. 403-409
    • Chibon, F.1    De Mascarel, I.2    Sierankowski, G.3
  • 7
    • 52549093971 scopus 로고    scopus 로고
    • High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system
    • Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21:1271-1277.
    • (2008) Mod Pathol , vol.21 , pp. 1271-1277
    • Gown, A.M.1    Goldstein, L.C.2    Barry, T.S.3
  • 8
    • 78349311452 scopus 로고    scopus 로고
    • The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays
    • Babic A, Loftin IR, Stanislaw S, et al. The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods. 2010;52:287-300.
    • (2010) Methods , vol.52 , pp. 287-300
    • Babic, A.1    Loftin, I.R.2    Stanislaw, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.